The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Research Report 2025
Synopsis
The global Chronic Obstructive Pulmonary Disease (COPD) Treatment market was valued at US$ 12890 million in 2023 and is anticipated to reach US$ 16110 million by 2030, witnessing a CAGR of 2.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disease (COPD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disease (COPD) Treatment.
Report Scope
The Chronic Obstructive Pulmonary Disease (COPD) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Obstructive Pulmonary Disease (COPD) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Disease (COPD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Boehringer Ingelheim International GmbH
GlaxoSmithKline
Novartis AG
Teva Pharmaceutical Industries
Sunovion Pharmaceuticals
CHIESI Farmaceutici
Orion Corporation
Mylan
Segment by Type
Corticosteroids
Phosphodiesterase Type 4 Inhibitors
Bronchodilators
Others
Segment by Application
Hospital
Clinic
Retail Pharmacies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disease (COPD) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Chronic Obstructive Pulmonary Disease (COPD) Treatment market was valued at US$ 12890 million in 2023 and is anticipated to reach US$ 16110 million by 2030, witnessing a CAGR of 2.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disease (COPD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disease (COPD) Treatment.
Report Scope
The Chronic Obstructive Pulmonary Disease (COPD) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Obstructive Pulmonary Disease (COPD) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Disease (COPD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Boehringer Ingelheim International GmbH
GlaxoSmithKline
Novartis AG
Teva Pharmaceutical Industries
Sunovion Pharmaceuticals
CHIESI Farmaceutici
Orion Corporation
Mylan
Segment by Type
Corticosteroids
Phosphodiesterase Type 4 Inhibitors
Bronchodilators
Others
Segment by Application
Hospital
Clinic
Retail Pharmacies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disease (COPD) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Corticosteroids
1.2.3 Phosphodiesterase Type 4 Inhibitors
1.2.4 Bronchodilators
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Retail Pharmacies
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Perspective (2019-2030)
2.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Growth Trends by Region
2.2.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Dynamics
2.3.1 Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry Trends
2.3.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers
2.3.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Challenges
2.3.4 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Disease (COPD) Treatment Players by Revenue
3.1.1 Global Top Chronic Obstructive Pulmonary Disease (COPD) Treatment Players by Revenue (2019-2024)
3.1.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue
3.4 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Concentration Ratio
3.4.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue in 2023
3.5 Chronic Obstructive Pulmonary Disease (COPD) Treatment Key Players Head office and Area Served
3.6 Key Players Chronic Obstructive Pulmonary Disease (COPD) Treatment Product Solution and Service
3.7 Date of Enter into Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Obstructive Pulmonary Disease (COPD) Treatment Breakdown Data by Type
4.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Forecasted Market Size by Type (2025-2030)
5 Chronic Obstructive Pulmonary Disease (COPD) Treatment Breakdown Data by Application
5.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (2019-2030)
6.2 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country (2019-2024)
6.4 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (2019-2030)
7.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country (2019-2024)
7.4 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (2019-2030)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (2019-2030)
9.2 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country (2019-2024)
9.4 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (2019-2030)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Treatment Introduction
11.1.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disease (COPD) Treatment Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Boehringer Ingelheim International GmbH
11.2.1 Boehringer Ingelheim International GmbH Company Detail
11.2.2 Boehringer Ingelheim International GmbH Business Overview
11.2.3 Boehringer Ingelheim International GmbH Chronic Obstructive Pulmonary Disease (COPD) Treatment Introduction
11.2.4 Boehringer Ingelheim International GmbH Revenue in Chronic Obstructive Pulmonary Disease (COPD) Treatment Business (2019-2024)
11.2.5 Boehringer Ingelheim International GmbH Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Treatment Introduction
11.3.4 GlaxoSmithKline Revenue in Chronic Obstructive Pulmonary Disease (COPD) Treatment Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Chronic Obstructive Pulmonary Disease (COPD) Treatment Introduction
11.4.4 Novartis AG Revenue in Chronic Obstructive Pulmonary Disease (COPD) Treatment Business (2019-2024)
11.4.5 Novartis AG Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Detail
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Disease (COPD) Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Chronic Obstructive Pulmonary Disease (COPD) Treatment Business (2019-2024)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Sunovion Pharmaceuticals
11.6.1 Sunovion Pharmaceuticals Company Detail
11.6.2 Sunovion Pharmaceuticals Business Overview
11.6.3 Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Treatment Introduction
11.6.4 Sunovion Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disease (COPD) Treatment Business (2019-2024)
11.6.5 Sunovion Pharmaceuticals Recent Development
11.7 CHIESI Farmaceutici
11.7.1 CHIESI Farmaceutici Company Detail
11.7.2 CHIESI Farmaceutici Business Overview
11.7.3 CHIESI Farmaceutici Chronic Obstructive Pulmonary Disease (COPD) Treatment Introduction
11.7.4 CHIESI Farmaceutici Revenue in Chronic Obstructive Pulmonary Disease (COPD) Treatment Business (2019-2024)
11.7.5 CHIESI Farmaceutici Recent Development
11.8 Orion Corporation
11.8.1 Orion Corporation Company Detail
11.8.2 Orion Corporation Business Overview
11.8.3 Orion Corporation Chronic Obstructive Pulmonary Disease (COPD) Treatment Introduction
11.8.4 Orion Corporation Revenue in Chronic Obstructive Pulmonary Disease (COPD) Treatment Business (2019-2024)
11.8.5 Orion Corporation Recent Development
11.9 Mylan
11.9.1 Mylan Company Detail
11.9.2 Mylan Business Overview
11.9.3 Mylan Chronic Obstructive Pulmonary Disease (COPD) Treatment Introduction
11.9.4 Mylan Revenue in Chronic Obstructive Pulmonary Disease (COPD) Treatment Business (2019-2024)
11.9.5 Mylan Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
